A brand new way
A Comprehensive Guide for Sydney Patients | Auscare Store
Introduction
A Comprehensive Guide for Sydney Patients: Neuropathic pain, also known as nerve pain or neuralgia, is a complex chronic pain condition that affects approximately 7-10% of the population worldwide . In Australia, up to 1 in 10 people live with neuropathic pain, which severely impacts quality of life and carries a substantial social and economic burden .
Unlike ordinary pain that signals tissue damage, neuropathic pain arises from damage or dysfunction within the nervous system itself . This makes it particularly challenging to treat with conventional pain relievers.
At Auscare Store, we provide educational resources to help Sydney patients understand their health conditions and treatment options. This guide explains the causes of neuropathic pain and explores evidence-based treatment approaches.
What Is Neuropathic Pain?
Neuropathic pain is defined as pain caused by a disease or injury affecting the somatosensory nervous system . It can result from damage to:
| Location | Description |
|---|---|
| Peripheral nerves | Nerves outside the brain and spinal cord |
| Spinal cord | Damage to nerve pathways within the spine |
| Brain | Central nervous system injury or disease |
Common Descriptions of Neuropathic Pain
Patients often describe neuropathic pain as:
-
Burning or hot sensation
-
Shooting or stabbing pain
-
Electric shock-like feelings
-
Pins and needles (paraesthesia)
-
Tingling or pricking sensations
-
Cold or squeezing discomfort
-
Numbness with associated pain
Key Features
-
Allodynia: Pain from non-painful stimuli, such as light touch or sheets brushing against the skin
-
Hyperalgesia: Increased sensitivity to painful stimuli
-
Often worse at night
-
Can be mild or severe, constant or intermittent
What Causes Neuropathic Pain?
Neuropathic pain can arise from various underlying conditions and injuries affecting the nervous system .
1. Metabolic Causes
| Condition | Description |
|---|---|
| Diabetic peripheral neuropathy | Nerve damage from high blood sugar levels; one of the most common causes |
| Vitamin B12 or thiamine (B1) deficiency | Nutritional deficiencies affecting nerve health |
2. Infectious Causes
| Condition | Description |
|---|---|
| Postherpetic neuralgia | Ongoing pain after shingles (herpes zoster) infection |
| HIV/AIDS | Associated neuropathy |
3. Structural & Mechanical Causes
| Condition | Description |
|---|---|
| Spinal cord injury | Damage to the spinal cord can cause neuropathic pain below the level of injury |
| Nerve compression or entrapment | Such as sciatica or carpal tunnel syndrome |
| Phantom limb pain | Pain after amputation |
4. Disease-Related Causes
| Condition | Description |
|---|---|
| Multiple sclerosis | Demyelinating disease affecting nerve transmission |
| Stroke | Central post-stroke pain |
| Cancer and its treatment | Radiation, surgery, or chemotherapy-induced nerve damage |
5. Other Causes
| Cause | Description |
|---|---|
| Heavy alcohol use | Alcoholic neuropathy |
| Autoimmune diseases | Conditions affecting peripheral nerves |
| Certain medications | Drug-induced neuropathy |
6. Idiopathic
In some cases, no specific cause can be identified despite thorough investigation .
How Is Neuropathic Pain Diagnosed?
Accurate diagnosis is essential for effective treatment. Your doctor will typically :
Clinical Assessment
-
Detailed history of symptoms and pain characteristics
-
Review of general health and medications
-
Physical examination including:
-
Muscle strength and coordination
-
Reflexes
-
Sensitivity to touch, pain, and temperature
-
Diagnostic Tests
| Test | Purpose |
|---|---|
| Blood tests | Identify underlying conditions (diabetes, vitamin deficiencies) |
| Nerve conduction studies | Measure how quickly nerves carry electrical signals |
| CT or MRI scans | Look for structural causes of nerve compression or damage |
Your doctor may refer you to a pain specialist or multidisciplinary pain clinic for further assessment and treatment .
💊 Evidence-Based Treatment Approaches
Treatment for neuropathic pain aims to relieve symptoms, improve function, and enhance quality of life . A combination of approaches is often most effective.
📋 First-Line Treatments (Strongest Evidence)
The 2025 International Association for the Study of Pain (NeuPSIG) guidelines recommend the following as first-line treatments :
| Medication Class | Examples | How They Work |
|---|---|---|
| Alpha-2 delta ligands | Gabapentin, Pregabalin | Bind to calcium channels, reduce excitatory transmitter release |
| Serotonin-norepinephrine reuptake inhibitors (SNRIs) | Duloxetine, Venlafaxine | Influence neurotransmitter levels to reduce pain |
| Tricyclic antidepressants (TCAs) | Amitriptyline, Nortriptyline | Modulate pain signaling pathways |
Important considerations :
-
These medicines have modest benefits and require careful patient screening
-
Close monitoring is essential
-
Effects vary between individuals
💊 Second-Line Treatments
| Treatment | Examples | Notes |
|---|---|---|
| Topical agents | Lidocaine patches, Capsaicin cream/patch | Small effects but high safety and tolerability; suitable for older adults or those on multiple medications |
| Tramadol | – | Weak opioid with SNRI properties |
| Combination therapies | – | May be more effective than single agents |
| Botulinum toxin A | – | For focal peripheral neuropathic pain |
⚕️ Third-Line Treatments
When first- and second-line treatments are insufficient :
| Treatment | Description |
|---|---|
| High-frequency repetitive transcranial magnetic stimulation (rTMS) | Non-invasive brain stimulation |
| Spinal cord stimulation | Implanted device sending electrical impulses to the spinal cord |
| Strong opioids | Reserved when no alternative available; significant risks of tolerance and dependence |
Note on spinal cord stimulation: Recent Australian Government reviews note that evidence for comparative clinical effectiveness of SCS compared to standard care is uncertain, and there remains doubt about the magnitude of clinical effect and long-term risks .
Treatments Not Recommended
The 2025 NeuPSIG guidelines recommended against :
-
Cannabis-based products – Found to be ineffective for neuropathic pain
-
Some treatments with inconclusive evidence:
-
SSRIs (e.g., escitalopram)
-
NMDA receptor antagonists (e.g., ketamine)
-
Implanted spinal cord stimulation (evidence insufficient)
-
Cannabis-Based Medicines and Neuropathic Pain
What the Research Shows
A 2025 systematic review examined 22 randomized controlled trials on cannabis-based medicines (CBMs) for neuropathic pain :
| Finding | Details |
|---|---|
| Significant pain reduction | Reported in 15 studies for conditions including multiple sclerosis, spinal cord injury, diabetic neuropathy, and HIV-associated neuropathy |
| No significant effect | 7 RCTs observed no significant pain relief compared to placebo |
| Secondary benefits | Some studies showed improvements in mood and sleep |
Limitations of Current Evidence
-
Small sample sizes in many studies
-
Short study durations
-
High placebo response rates
-
Trial unblinding due to psychoactive effects of cannabinoids
-
Difficulty extrapolating to chronic pain conditions
Expert Recommendations
The 2025 NeuPSIG guidelines specifically recommended against cannabis-based products for neuropathic pain, finding them ineffective .
The Auscare Store Perspective
At Auscare Store, we provide educational information only. While some patients may consider medicinal cannabis or pain killers, the current evidence base does not support its use for neuropathic pain. Patients should always consult their doctor about appropriate treatment options.
Non-Drug Treatment Approaches
Non-pharmacological approaches are essential components of comprehensive pain management .
Lifestyle Measures
| Approach | Benefits |
|---|---|
| Regular exercise | Releases endorphins (natural pain relievers); reduces muscle stiffness |
| Balanced diet | Supports overall health and nerve function |
| Pacing activities | Breaking tasks into manageable steps to avoid pain flares |
| Good sleep hygiene | Poor sleep increases pain sensitivity |
Psychological Approaches
| Approach | Description |
|---|---|
| Cognitive Behavioral Therapy (CBT) | Helps retrain the brain and develop coping strategies |
| Relaxation techniques | Meditation, deep breathing, hypnosis |
| Pain education | Understanding pain mechanisms reduces fear and improves outcomes |
Physical Therapies
| Therapy | Application |
|---|---|
| Physiotherapy | Maintains flexibility and function |
| Transcutaneous electrical nerve stimulation (TENS) | May help some patients |
| Yoga and meditation | Mind-body approaches for pain management |
Self-Management Strategies
-
Develop a Pain Flare-Up Plan
-
Set realistic goals for activities
-
Build a support team (GP, specialists, psychologists)
-
Be patient and persistent – changes take time
Australian Context: PBS Medications
In Australia, several medications for neuropathic pain are available on the Pharmaceutical Benefits Scheme (PBS).
PBS-Listed Medications
| Medication | PBS Listing Information |
|---|---|
| Pregabalin (Lyrica®) | Listed for neuropathic pain with Authority Required (STREAMLINED). Patients must meet specific criteria . |
| Gabapentin | Available on PBS for neuropathic pain |
| Amitriptyline | Tricyclic antidepressant, widely used for nerve pain |
| Duloxetine | SNRI listed for neuropathic pain |
Prescribing Requirements
For PBS-subsidised pregabalin, patients must :
-
Have an Authority Required prescription
-
Meet specific clinical criteria
-
Show adequate clinical response for continuation
Note: Pregabalin is not subsidised for fibromyalgia, acute pain, or chronic pain of non-neuropathic origin .
Driving and Medications
Many medications used for neuropathic pain can affect driving ability:
-
Sedation and drowsiness are common side effects of gabapentinoids and TCAs
-
Patients should not drive if affected
-
Discuss driving safety with your doctor
In NSW, driving under the influence of drugs that impair driving is illegal. Always follow medical advice regarding driving restrictions.
When to Seek Specialist Help
Consider referral to a pain specialist or multidisciplinary pain clinic if :
| Indicator | Description |
|---|---|
| Declining physical function | Pain interfering with daily activities |
| Red flags present | New pain with neurological changes, autonomic dysreflexia, bladder/bowel changes |
| Psychological distress | K10 > 19, Orebro > 50, BPI interference > 50 |
| Medication concerns | Opioid dose > 40mg morphine equivalent/day, duration > 90 days |
| Multiple medications | Complex regimens with side effects |
| Poor response | Pain not responding to primary care treatment |
Pain Services in NSW
-
Pain killer clinics like Auscare store
-
Tertiary referral services for complex cases
-
Multidisciplinary pain centres offering comprehensive assessmen

